Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 14/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22805547 | 0.87 | PDE2A (0.50) | PDE2AKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL18343699 | 0.82 | PDE2A (0.49) | PDE2AKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL24393156 | 0.82 | PDE2A (0.62) | PDE2AKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL29685062 | 0.81 | PDE2A (0.60) | PDE2AKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL30095667 | 0.81 | PDE2A (0.60) | PDE2AKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL17889388 | 0.81 | PDE2A (0.47) | PDE2AKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL24954062 | 0.81 | PDE2A (0.47) | PDE2AKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL31106964 | 0.81 | PDE2A (0.47) | PDE2AKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL31194523 | 0.79 | PDE2A (0.42) | PDE2AKMT2AGAACYP1A2CYP3A4 | |
| SCHEMBL174841 | 0.79 | PDE2A (0.42) | PDE2AKMT2AGAACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4536362-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | Incyte Corporation (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250066363-A1 | Bicyclic DGK Inhibitors | INCYTE CORPORATION | 2025-02-27 | — | — | US | disclosed |
| WO-2025043151-A2 | BICYCLIC DGK INHIBITORS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024249380-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| WO-2009023978-A1 | PYRAZOLO [3,4 -D] PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF PROTEIN KINASE | ONCALIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| EP-2025678-A1 | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase | Oncalis AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025678-A1 | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase | Oncalis AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | PDE2A 1132/4885KMT2A 953/4885GAA 1488/4885 |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | PDE2A 129/4885KMT2A 4508/4885GAA 1454/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | PDE2A 1179/4885KMT2A 785/4885GAA 2824/4885 |
| US-20250066363-A1 | Bicyclic DGK Inhibitors | DGKA, DGKG, DGKK | PDE2A 2075/4885KMT2A 2716/4885GAA 964/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | PDE2A 23/4885KMT2A 3970/4885GAA 189/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | PDE2A 1443/4885KMT2A 4296/4885GAA 115/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | PDE2A 1132/4885KMT2A 953/4885GAA 1488/4885 |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | PDE2A 1549/4885KMT2A 3504/4885GAA 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.